Combined locoregional and systemic therapy for advanced hepatocellular carcinoma: finally, the future is obscure.
作者信息
Farsad Khashayar, Nabavizadeh Nima, Kardosh Adel, Jou Janice H, Naugler Willscott E, Kolbeck Kenneth J
机构信息
Department of Interventional Radiology, Dotter Interventional Institute, Oregon Health and Science University, Portland, OR, USA.
Department of Radiation Oncology, Oregon Health and Science University, Portland, OR, USA.
出版信息
Ann Transl Med. 2020 Dec;8(24):1700. doi: 10.21037/atm-20-4164.
Abstract
摘要
相似文献
1
Combined locoregional and systemic therapy for advanced hepatocellular carcinoma: finally, the future is obscure.
Ann Transl Med. 2020 Dec;8(24):1700. doi: 10.21037/atm-20-4164.
2
Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
Cochrane Database Syst Rev. 2016 Feb 16;2:CD011313. doi: 10.1002/14651858.CD011313.pub2.
3
Battle Royale: Systemic Versus Locoregional Therapy for Unresectable Hepatocellular Carcinoma.
AJR Am J Roentgenol. 2018 Jun;210(6):1366-1367. doi: 10.2214/AJR.17.19392. Epub 2018 Apr 18.
4
5
Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma.
Cancer Control. 2017 Jul-Sep;24(3):1073274817729243. doi: 10.1177/1073274817729243.
6
Combined transarterial targeting locoregional immunotherapy-chemotherapy for patients with unresectable hepatocellular carcinoma: a new alternative for an old problem.
J Interferon Cytokine Res. 1995 May;15(5):467-72. doi: 10.1089/jir.1995.15.467.
7
Systemic treatment of advanced hepatocellular cancer: new hope on the horizon.
Expert Rev Anticancer Ther. 2019 Apr;19(4):343-353. doi: 10.1080/14737140.2019.1585245. Epub 2019 Mar 11.
8
Treatment of hepatocellular carcinoma: present and future.
Expert Rev Anticancer Ther. 2013 Apr;13(4):469-79. doi: 10.1586/era.13.21.
9
Imaging assessment of hepatocellular carcinoma response to locoregional and systemic therapy.
AJR Am J Roentgenol. 2013 Jul;201(1):80-96. doi: 10.2214/AJR.13.10706.
10
A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy: implication for patient selection in systemic therapy trials.
Cancer. 2008 Nov 15;113(10):2742-51. doi: 10.1002/cncr.23878.
引用本文的文献
1
Exploring the Role of Patient Preferences in Hepatocellular Carcinoma Treatment Decisions: A Qualitative Study.
MDM Policy Pract. 2025 May 29;10(1):23814683251340055. doi: 10.1177/23814683251340055. eCollection 2025 Jan-Jun.
2
A Comparative Study of Antitumor Immunity Induced by Radiofrequency Microwave and Cryoablation in Hepatocellular Carcinoma.
Appl Biochem Biotechnol. 2024 Jul;196(7):4088-4104. doi: 10.1007/s12010-023-04760-y. Epub 2023 Oct 27.
3
Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements.
Liver Cancer. 2022 Jan 4;11(3):192-208. doi: 10.1159/000521596. eCollection 2022 Jun.
4
Percutaneous Therapies for Hepatocellular Carcinoma: Evolution of Liver Directed Therapies.
J Hepatocell Carcinoma. 2021 Sep 23;8:1181-1193. doi: 10.2147/JHC.S268300. eCollection 2021.
本文引用的文献
1
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
2
Yttrium-90 Radioembolization for BCLC Stage C Hepatocellular Carcinoma Comparing Child-Pugh A Versus B7 Patients: Are the Outcomes Equivalent?
Cardiovasc Intervent Radiol. 2020 May;43(5):721-731. doi: 10.1007/s00270-020-02434-4. Epub 2020 Mar 5.
3
Efficacy and Safety of Liver-Directed Concurrent Chemoradiotherapy and Sequential Sorafenib for Advanced Hepatocellular Carcinoma: A Prospective Phase 2 Trial.
Int J Radiat Oncol Biol Phys. 2020 May 1;107(1):106-115. doi: 10.1016/j.ijrobp.2020.01.027. Epub 2020 Feb 19.
4
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.
J Clin Oncol. 2020 Jan 20;38(3):193-202. doi: 10.1200/JCO.19.01307. Epub 2019 Dec 2.
5
Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials.
Liver Cancer. 2019 Jul;8(4):221-238. doi: 10.1159/000501501. Epub 2019 Jul 9.
6
A global view of hepatocellular carcinoma: trends, risk, prevention and management.
Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):589-604. doi: 10.1038/s41575-019-0186-y. Epub 2019 Aug 22.
7
Insights into the success and failure of systemic therapy for hepatocellular carcinoma.
Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):617-630. doi: 10.1038/s41575-019-0179-x. Epub 2019 Aug 1.
8
Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma.
World J Gastroenterol. 2019 May 28;25(20):2416-2429. doi: 10.3748/wjg.v25.i20.2416.
9
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol. 2019 Feb;20(2):282-296. doi: 10.1016/S1470-2045(18)30937-9. Epub 2019 Jan 18.
10
Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis.
Radiat Oncol. 2018 Sep 25;13(1):188. doi: 10.1186/s13014-018-1136-5.
Zotero 插件